Posted by Michael Wonder on 15 May 2022
PHARMAC publishes agenda for May 2022 PTAC meeting
12 May 2022 - Yet another PTAC meeting with very few applications for new medicines/medicines still under patent protection.
The PTAC will consider applications for the following medicines when it meets next week:
- Osimertinib mesylate for non-small-cell lung cancer
- Upadacitinib monohydrate for psoriatic arthritis and ankylosing spondylitis
- Bevacizumab for advanced ovarian cancer
- Sodium hypochlorite for eczema in cases with secondary bacterial infection
- Testosterone for transdermal hormone therapy
